FDA Keen On Lilly’s Prasugrel: Will Advisory Committee Follow Suit?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA says that increased risk of bleeding for prasugrel’s clear cardiovascular efficacy is a “reasonable trade.”
You may also be interested in...
The Return Of The Blockbuster? Stage Is Set For Prasugrel Approval
FDA's handling of the advisory committee meeting for Lilly/Daiichi Sankyo's platelet inhibitor prasugrel is the first signal in some time that the agency is ready to approve a primary care drug to be used in large patient populations with relatively limited restrictions
The Return Of The Blockbuster? Stage Is Set For Prasugrel Approval
FDA's handling of the advisory committee meeting for Lilly/Daiichi Sankyo's platelet inhibitor prasugrel is the first signal in some time that the agency is ready to approve a primary care drug to be used in large patient populations with relatively limited restrictions
Prasugrel REMS: Lilly Proposes MedGuide, FDA Wants More To Mitigate Risks
Lilly’s proposed REMS consists only of a Medication Guide warning of bleeding risk; FDA suggests the addition of a communication plan regarding the possible cancer risk.